Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

1.3K
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.3K
Atypical Pneumonia01:14

Atypical Pneumonia

47
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
47
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

1.2K
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.2K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

4.2K
The pathophysiology of pneumonia involves the following steps:
4.2K
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.1K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

4.0K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
4.0K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Pulmonary Angiopathy in Severe COVID-19: Physiological Conclusions Derived from Ventilatory Ratio?

American journal of respiratory and critical care medicine·2020
Same author

Biomarkers in the ICU: less is more? No.

Intensive care medicine·2020
Same author

Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020).

European respiratory review : an official journal of the European Respiratory Society·2020
Same author

Reconsidering ventilator-associated pneumonia from a new dimension of the lung microbiome.

EBioMedicine·2020
Same author

Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia.

Annals of the American Thoracic Society·2020
Same author

Aetiological diagnosis in new adult outpatients with bronchiectasis:role of predictors derived from real life experience.

Respiratory medicine·2020
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Apr 5, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.8K

コミュニティで得られた肺炎

Elena Prina1, Otavio T Ranzani2, Antoni Torres1

  • 1Department of Pulmonology, Hospital Clinic of Barcelona, University of Barcelona, Institut D'investigacions August Pi I Sunyer (IDIBAPS), Ciber de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.

Lancet (London, England)
|August 17, 2015
PubMed
まとめ
この要約は機械生成です。

地域感染性肺炎の効果的な治療には 個別化された抗生物質療法と 細心の追跡が必要です このアプローチは,抗生物質耐性を低減し,患者のアウトカムを改善し,適時な経口シフトと臨床安定基準を強調することを目的としています.

さらに関連する動画

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

24.2K
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

9.6K

関連する実験動画

Last Updated: Apr 5, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.8K
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

24.2K
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

9.6K

科学分野:

  • 感染症
  • 肺科
  • 薬理学について

背景:

  • 地域感染性肺炎 (CAP) は,世界的な死亡率,罹病率,および経済的負担を伴う.
  • 実験的な抗生物質の選択は CAPの管理に不可欠ですが,誤った使用は耐性や有害な効果に寄与します.

研究 の 目的:

  • CAPの効果的な個別化された抗生物質治療の原則を概説する.
  • フォローアップの重要性,早期の口服の切り替え,そして抗生物質の管理を強調する.
  • 新しい診断方法とCAPの長期的な影響について議論する.

主な方法:

  • 地域感染性肺炎の現在の管理戦略のレビュー
  • 抗生物質管理の原則と臨床的安定性基準の議論
  • 肺の超音波検査や 分子検査などの 新興診断技術の探索

主要な成果:

  • 最適な抗生物質の使用は 耐性や副作用を軽減することができます
  • 早期に口服用抗生物質への移行と 治療期間を調整することが重要です
  • 先進的な診断技術により より迅速で正確な診断が可能になります

結論:

  • 個別化され,証拠に基づいた抗生物質戦略は,CAPの管理に不可欠です.
  • 最適な結果を出すには 患者の注意深い監視と管理が不可欠です
  • 長期のCAPの続編と管理に関するさらなる研究が必要である.